Ongoing Projects

HOME > R&D Pipeline > Current status > Ongoing Projects

KDDF-201812-16 Development of oral drug for the treatment of amyotrophic lateral sclerosis(CNS Diseases, Chemical) [2019-07-29]

PRINT
Ongoing Project
Section Lead
Generation
Lead
Optimization
Preclinical Phase I Phase II Phase III

Development and Market Objectives

Development of novel drug enable effective oral administration for Amyotrophic lateral sclerosis (ALS)

Unmet Medical Need & Target Patients

-   Unmet Medical Needs

: ALS is a fatal neurodegenerative disease in which more than 90% of the patients die within 3-4 years after disease onset.

: Edaravone, the most effective treatment currently, for ALS requires IV infusion on a regular dosing schedule (administration-drug free period). For this reason, the patients with ALS symptoms suffer from periodic treatment in a hospital. There is a limitation of sustained bioactivity by the current edaravone IV infusion.

: TEJ-1704 developed as an orally administrable derivative of edaravone that maintains drug efficacy. And it will contribute to the convenience of chronic treatment of patients and the reduction of accompanying social costs.

Status

: Water solubility enhancement of TEJ-1704 versus Edaravones was observed.

: In study of oral administration of TEJ-1704 in rodent models, edaravone with  concentration in blood was increased by 12.4 times compared to edaravone-oral.

Intellectual Property

Theragen Etex Co., Ltd. filed a patent for the material patent on the results of the previous research

Competitive Advantages

: TEJ-1704 exhibits excellent chemical stability and good solubility in water, thus securing the reliability of various bioassays. It also shows sufficient bioavailability and pharmacokinetic profile to enable oral administration for patient convenience.

Contact & Company Overview

Related Project

Related Project
list
Update to 2013 © KOREA DRUG DEVELOPMENT FUND. ALL RIGHTS RESERVED. QR Code